Advanced cell analysis is becoming a strategic accelerator for life science organizations that need faster, higher confidence decisions in discovery and development. At the Global BioInnovation Forum conversation, Wenbin Jiang, CEO of Cytek Biosciences, joins Fern Lazar, Managing Partner and Global Health Practice Leader at FINN Partners, to discuss how full spectral profiling in flow cytometry expands cell analysis and supports biomarker decisions across immuno-oncology, vaccines, and cell and gene therapy. High dimensional insight tightens iteration cycles and helps translate biological complexity into decisions that accelerate innovation and strengthen patient impact.